research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Effects of Short-Term Finasteride on Apoptotic Factors and Androgen Receptors in Prostate Cancer Cells
Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
research Multiple readout assay for hormonal (androgenic and antiandrogenic) and cytotoxic activity of plant and fungal extracts based on differential prostate cancer cell line behavior
The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
research Selective Androgen Receptor Modulators (SARMs) Negatively Regulate Triple-Negative Breast Cancer Growth and Epithelial:Mesenchymal Stem Cell Signaling
SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
research IMPACT OF LOW DOSE FINASTERIDE FOR THE TREATMENT OF ANDROGENIC ALOPECIA ON SERUM PROSTATE SPECIFIC ANTIGEN (PSA) LEVELS IN MEN PARTICIPATED IN POPULATION-BASED SCREENING FOR PROSTATE CANCER
Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
research Exercise in dermatology: Exercise’s influence on skin aging, skin cancer, psoriasis, venous ulcers, and androgenetic alopecia
Exercise helps reduce skin aging, prevent psoriasis, and improve venous ulcers.
research What’s new in androgenetic alopecia: approvals, long-term safety data, cancer risk and treatment options for women.
research Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.
research Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial
Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
research The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
research Male pattern baldness and the risk of prostate cancer
Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.
research Finasteride-its impact on sexual function and prostate cancer
Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
research CAG Repeat Testing of Androgen Receptor Polymorphism: Is This Necessary for the Best Clinical Management of Hypogonadism?
Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.
research Hormonal prevention of prostate cancer
Suppressing certain hormones might help prevent prostate cancer.
research Non-canonical dimerization of the androgen receptor and other nuclear receptors: implications for human disease
Mutations in certain receptors can cause diseases and offer new treatment options.
research Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women
Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.
research Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
research Anti-Androgen Effects of Extracts and Compounds fromGanoderma lucidum
Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.
research Association of Spironolactone Use With Risk of Cancer
Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.
research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
research Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis
Taking spironolactone doesn't increase the chance of breast cancer coming back.
research Baldness and testicular cancer: the EPSAM case-control study
Bald men may have a lower risk of testicular cancer.
research Prostate cancer update: 2007
2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
research 5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
research Cutaneous malignant melanoma incidences analyzed worldwide by skin type over advancing age of males and females: Evidence estrogen and androgenic hair are risk factors
Estrogen and androgenic hair increase melanoma risk, especially in European-ancestry individuals.
research Hair, Hormones, and High-Risk Prostate Cancer
Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.
research Researchers Link Early Hair Loss and Prostate Cancer
Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.
research Androgenetic alopecia - just a cosmetic defect or a biomarker and risk factor for systemic diseases? - literature review
Androgenetic alopecia may indicate higher risk for certain diseases and mental health issues.